Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000491804 | SCV000580630 | pathogenic | Hereditary cancer-predisposing syndrome | 2019-01-30 | criteria provided, single submitter | clinical testing | The c.2635-1G>A intronic pathogenic mutation results from a G to A substitution one nucleotide upstream from coding exon 16 of the MSH2 gene. This alteration has been identified in identified in 1/369 Swedish Lynch syndrome families (Lagerstedt-Robinson K et al. Oncol. Rep. 2016 Nov;36:2823-2835). In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. |
Myriad Genetics, |
RCV003449378 | SCV004186746 | likely pathogenic | Lynch syndrome 1 | 2023-08-10 | criteria provided, single submitter | clinical testing | This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function. |
Baylor Genetics | RCV003449378 | SCV004196847 | pathogenic | Lynch syndrome 1 | 2023-05-10 | criteria provided, single submitter | clinical testing |